<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157858</url>
  </required_header>
  <id_info>
    <org_study_id>CSMS995 ANLIIT</org_study_id>
    <nct_id>NCT01157858</nct_id>
  </id_info>
  <brief_title>Everolimus and LongActing Octreotide Trial in Polycystic Livers</brief_title>
  <acronym>ELATE</acronym>
  <official_title>Everolimus Added to Long Acting Octreotide as a Volume Reducing Treatment of Polycystic Livers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to reduce polycystic liver volume by treating with octreotide,&#xD;
      whether or not combined with everolimus; to assess whether combination therapy of everolimus&#xD;
      and octreotide gives a bigger reduction of polycystic liver volume than octreotide&#xD;
      monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center randomized, open-label, parallel study comparing the safety and&#xD;
      efficacy of everolimus-octreotide LAR treatment to monotherapy octreotide LAR in adult&#xD;
      symptomatic patients with polycystic livers because of polycystic liver disease (PCLD).&#xD;
&#xD;
      We aim to include 44 patients affected by a polycystic liver either due to PCLD, 22 patients&#xD;
      in the combination group and 22 patients in the mono therapy group.The duration of the trial&#xD;
      will be 52 weeks. The treatment will be 48 weeks and the last control visit will take place&#xD;
      four weeks after the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver volume</measure>
    <time_frame>at baseline and at 12 months</time_frame>
    <description>change of total liver volume in terms of percentage from baseline to 12 months as determined by CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Change in symptoms, measured by GI-questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Change in quality of life, measured by EuroQoL-questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responders</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Proportion of patients having any reduction in total liver volume after 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During 12 months of treatment</time_frame>
    <description>Adverse events that occur in these 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Polycystic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Everolimus + octreotide LAR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Octreotide LAR combined with everolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octreotide LAR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Octreotide LAR monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>2.5 mg every day orally</description>
    <arm_group_label>Everolimus + octreotide LAR</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide LAR</intervention_name>
    <description>40 mg every 28 days IM</description>
    <arm_group_label>Everolimus + octreotide LAR</arm_group_label>
    <arm_group_label>Octreotide LAR</arm_group_label>
    <other_name>Sandostatine LAR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 &lt; age ≤ 70 years&#xD;
&#xD;
          -  Polycystic liver disease (PCLD), defined as ≥ 20 liver cysts&#xD;
&#xD;
          -  Total liver volume must be at least 2500 mL&#xD;
&#xD;
          -  Symptomatic defined as ECOG-PS ≥ 1 (see fig 3.1)38, and having at least three out of&#xD;
             ten PCLD symptoms:&#xD;
&#xD;
          -  Abdominal pain&#xD;
&#xD;
          -  Abdominal distension&#xD;
&#xD;
          -  Abdominal fullness&#xD;
&#xD;
          -  Dyspnea&#xD;
&#xD;
          -  Early satiety&#xD;
&#xD;
          -  Back pain&#xD;
&#xD;
          -  Nausea/vomiting&#xD;
&#xD;
          -  Anorexia&#xD;
&#xD;
          -  Weight loss&#xD;
&#xD;
          -  Jaundice&#xD;
&#xD;
          -  Informed consent, patients are willing and able to comply with the study drug regimen&#xD;
             and all other study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ADPKD patients&#xD;
&#xD;
          -  Use of oral anticonceptives or estrogen supplementation&#xD;
&#xD;
          -  Females who are pregnant or breast-feeding or patients of reproductive potential not&#xD;
             employing an effective method of birth control. Women of childbearing potential must&#xD;
             have a negative serum pregnancy test within 48 hours prior to the administration of&#xD;
             study medication.&#xD;
&#xD;
          -  Intervention (aspiration or surgical intervention) within three months before baseline&#xD;
&#xD;
          -  Treatment with somatostatin analogues within three months before baseline&#xD;
&#xD;
          -  Patients with a kidney transplant&#xD;
&#xD;
          -  History or other evidence of chronic pulmonary disease associated with functional&#xD;
             limitation&#xD;
&#xD;
          -  History of severe cardiac disease (eg, NYHA Functional Class III or IV, myocardial&#xD;
             infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment,&#xD;
             unstable angina or other significant cardiovascular diseases). In addition, patients&#xD;
             with documented or presumed coronary artery disease or cerebrovascular disease should&#xD;
             not be enrolled.&#xD;
&#xD;
          -  History or other evidence of severe illness or any other conditions which would make&#xD;
             the patient, in the opinion of the investigator, unsuitable for the study&#xD;
&#xD;
          -  Symptomatic gallstones (octreotide decreases gall bladder volume)&#xD;
&#xD;
          -  Hypercholesterolemia (fasting cholesterol &gt; 8 mmol/l) or hypertriglyceridaemia (&gt; 5&#xD;
             mmol/l) not controlled by lipid lowering therapy&#xD;
&#xD;
          -  Granulocytopenia (white blood cell &lt; 3,000/mm3) or thrombocytopenia (platelets &lt;&#xD;
             100,000/mm3)&#xD;
&#xD;
          -  Infection with hepatitis B, hepatitis C, HIV, TBC (in medical history)&#xD;
&#xD;
          -  Mental illness that interferes with the patient ability to comply with the protocol&#xD;
&#xD;
          -  Drug or alcohol abuse within one year of baseline&#xD;
&#xD;
          -  Co-medication with strong inhibitor of CYP3A4 and or P-gp like voriconazole,&#xD;
             ketoconazole, diltiazem, verapamil, erythromycin or with a strong CYP3A4 and or P-gp&#xD;
             inductor like rifampicin&#xD;
&#xD;
          -  Known hypersensitivity to everolimus or one of its excipients&#xD;
&#xD;
          -  Enrolment in another clinical trial of an investigational agent while participating in&#xD;
             this study&#xD;
&#xD;
          -  Moderate or severe reaction on contrast in medical history&#xD;
&#xD;
          -  Treatment with I131 during the course of the trial&#xD;
&#xD;
          -  Use of metformin&#xD;
&#xD;
          -  Morbus Kahler or Morbus Waldenstrom with excretion of light chains in urine in medical&#xD;
             history&#xD;
&#xD;
          -  Kidney dysfunction (MDRD-GFR &lt; 60 ml/min/1.73m2 and ECC &lt; 60 ml/min, calculated by the&#xD;
             Cockcroft-Gault formula); in case of decreased body muscle mass, exact ECC is measured&#xD;
             using serum and urine creatinine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost PH Drenth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melissa Chrispijn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>July 6, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2010</study_first_posted>
  <last_update_submitted>June 26, 2015</last_update_submitted>
  <last_update_submitted_qc>June 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>Joost Drenth</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>liver cyst</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

